Concentrated on infusion solution. Clear colorless to pale yellow solution.
Anticoagulation in adult patients with heparin-induced type II thrombocytopenia requiring parenteral antithrombotic therapy. The diagnosis should be confirmed by HIPAA (heparin-induced platelet activation assay) or an equivalent test. However, such confirmation must not delay the start of treatment.
Novastan 100 mg / ml concentrate for solution for infusion. Name of the medicinal product : Novastan 100 mg / ml concentrate for solution for infusion.
Qualitative and quantitative composition : One ml concentrate for solution for infusion contains 100 mg argatroban monohydrate. One vial of 2.5 ml concentrate for solution for infusion contains 250 mg argatroban monohydrate. Final concentration after dilution as recommended is 1 mg / ml.
Excipients: 1 ml solution contains 400 mg ethanol (50% by volume) and 300 mg sorbitol. For a complete list of excipients, see the Summary of Product Characteristics. Novastan is contraindicated in patients with uncontrolled bleeding, hypersensitivity to argatroban or to any of the excipients and in patients with severe hepatic impairment.
For more information:
The page was last updated on 21/09/2020